ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.487,15
0,26%
S&P 500
5.178,19
-0,18%
Dow Jones
38.877,81
-0,02%
Euro vs US Dollar
1,07502
0,00%
Bitcoin
62.229,04
-0,17%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Akero Therapeutics Inc (AKRO)

  7. Akero Therapeutics Inc (AKRO) News

AKRO

Akero Therapeutics (AKRO)

Akero Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AKRO
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202413h00GlobeNewswire Inc.Akero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:AKROAkero Therapeutics Inc
30/04/202414h00GlobeNewswire Inc.Akero Therapeutics Appoints Scott Gangloff as Chief Technology OfficerNASDAQ:AKROAkero Therapeutics Inc
08/03/202422h02GlobeNewswire Inc.Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
07/03/202422h01GlobeNewswire Inc.Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and HepatologyNASDAQ:AKROAkero Therapeutics Inc
07/03/202402h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
07/03/202402h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
06/03/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
06/03/202423h16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
06/03/202403h13GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
05/03/202423h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
05/03/202412h05IH Market NewsAMD Hits Regulatory Roadblock, GitLab’s Stock Tumbles on Disappointing Earnings, and Latest NewsNASDAQ:AKROAkero Therapeutics Inc
04/03/202423h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
04/03/202423h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
04/03/202423h21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
04/03/202422h21GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
04/03/202413h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
04/03/202412h00GlobeNewswire Inc.Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY StudyNASDAQ:AKROAkero Therapeutics Inc
29/02/202422h42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKROAkero Therapeutics Inc
29/02/202414h00GlobeNewswire Inc.Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASHNASDAQ:AKROAkero Therapeutics Inc
29/02/202413h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AKROAkero Therapeutics Inc
29/02/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
29/02/202413h00GlobeNewswire Inc.Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
14/02/202403h40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AKROAkero Therapeutics Inc
03/01/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
03/01/202414h15GlobeNewswire Inc.Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
30/12/202302h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
30/12/202300h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202302h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202302h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
19/12/202302h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKRO

Kürzlich von Ihnen besucht

NASDAQ
GOOGL
Alphabet
NYSE
NKE
Nike
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
NYSE
MCD
McDonalds
DBI
SDXP
SDAX
NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
AMEX
XLF
Financial Select Sector
NYSE
XOM
Exxon Mobil
DBI
TDXP
Tec DAX
CCOM
SILVER
SILVER
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten